MSD, Pfizer try to stop three Steglatro generics

Merck Sharp & Dohme (MSD) and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro (ertugliflozin)—a diabetes treatment that Pfizer licences to MSD.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

Generics

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

Generics

‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole

18 February 2024 While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.

More features

‘All voices must be heard’: New CIPA president sets out plans for 2026

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Novo Nordisk secures China win ahead of key patent expiration

MSD, Pfizer try to stop three Steglatro generics

More on this story

Editor's picks

Editor's picks

More features